Cen Guo

5PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersPharmaceutical delivery technologiesPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 13, 2026
AI-Powered Lesion-Level Tumor Growth Inhibition Modeling Improves Model Stability and Prognostic Association With PFS.

|Dec 11, 2025
Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence.

Diane Wang, Cathy Cen Guo, Xizhe Gao

|Nov 17, 2022
PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.

Cen Guo, Kai H Liao, Meng Li

|Oct 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.

Omid Hamid, Alberto A Chiappori, John A Thompson

|Mar 05, 2020
Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-Cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk.

Katsuaki Ito, Noora Sjöstedt, Melina M Malinen

Pageof 1

Frequent Collaborators

1 joint publications

Liza DeAnnuntis

1 joint publications

Alan Liu

1 joint publications

Chong Duan

1 joint publications

Kevin Maresca